[go: up one dir, main page]

MX2020002682A - Metodos de dosificacion intranasal de metoclopramida. - Google Patents

Metodos de dosificacion intranasal de metoclopramida.

Info

Publication number
MX2020002682A
MX2020002682A MX2020002682A MX2020002682A MX2020002682A MX 2020002682 A MX2020002682 A MX 2020002682A MX 2020002682 A MX2020002682 A MX 2020002682A MX 2020002682 A MX2020002682 A MX 2020002682A MX 2020002682 A MX2020002682 A MX 2020002682A
Authority
MX
Mexico
Prior art keywords
dosing
methods
intranasal metoclopramide
metoclopramide
intranasal
Prior art date
Application number
MX2020002682A
Other languages
English (en)
Inventor
David A Gonyer
Marilyn R Carlson
Matthew J D'onofrio
Wayne Alves
Original Assignee
Evoke Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evoke Pharma Inc filed Critical Evoke Pharma Inc
Publication of MX2020002682A publication Critical patent/MX2020002682A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Otolaryngology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente descripción se refiere a métodos de dosificación intranasal de metoclopramida.
MX2020002682A 2017-09-11 2018-09-10 Metodos de dosificacion intranasal de metoclopramida. MX2020002682A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762556904P 2017-09-11 2017-09-11
US201762575302P 2017-10-20 2017-10-20
US201762595323P 2017-12-06 2017-12-06
US201862631366P 2018-02-15 2018-02-15
PCT/US2018/050191 WO2019051366A1 (en) 2017-09-11 2018-09-10 METHODS OF INTRANASAL DELIVERY OF METOCLOPRAMIDE

Publications (1)

Publication Number Publication Date
MX2020002682A true MX2020002682A (es) 2020-10-05

Family

ID=65635215

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020002682A MX2020002682A (es) 2017-09-11 2018-09-10 Metodos de dosificacion intranasal de metoclopramida.

Country Status (5)

Country Link
US (1) US20200276139A1 (es)
EP (1) EP3681573A4 (es)
CA (1) CA3075407A1 (es)
MX (1) MX2020002682A (es)
WO (1) WO2019051366A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130213393A1 (en) 2009-12-22 2013-08-22 Evoke Pharma, Inc. Nasal formulations of metoclopramide
US11517545B2 (en) 2016-12-15 2022-12-06 Evoke Pharma, Inc. Treatment of moderate and severe gastroparesis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770262B2 (en) * 2000-03-30 2004-08-03 Questcor Pharmaceuticals, Inc. Nasal administration of agents for the treatment of gastroparesis
US20130213393A1 (en) * 2009-12-22 2013-08-22 Evoke Pharma, Inc. Nasal formulations of metoclopramide
EP2747561B1 (en) * 2011-08-25 2018-05-09 Evoke Pharma, Inc. Treatment of symptoms associated with female gastroparesis

Also Published As

Publication number Publication date
EP3681573A4 (en) 2021-08-04
US20200276139A1 (en) 2020-09-03
WO2019051366A1 (en) 2019-03-14
CA3075407A1 (en) 2019-03-14
EP3681573A1 (en) 2020-07-22

Similar Documents

Publication Publication Date Title
PH12018500711A1 (en) Anti-pd1 antibodies and methods of use
PH12020550781A1 (en) Anti-jagged1 antibodies and methods of use
ZA201902141B (en) Acid-alpha glucosidase variants and uses thereof
PH12017500877A1 (en) ANTI-CD79b ANTIBODIES AND METHODS OF USE
PH12018500950B1 (en) Subcutaneous formulations of anti-cd38 antibodies and their uses
PH12017500982A1 (en) Heterodimeric antibodies that bind cd3 and cd38
PH12016501763B1 (en) Multispecific antibodies
ZA201902140B (en) Acid-alpha glucosidase variants and uses thereof
PH12020550871A1 (en) Process for the preparation of opicapone and intermediates thereof
ZA201800804B (en) Novel anti-human gpvi antibodies and uses thereof
MX2020012893A (es) Formulaciones de proteinas.
MX2017011223A (es) Variantes de protoxina ii y metodos de uso.
IN2013MU00848A (es)
MX2017016623A (es) Variantes de quimosina con propiedades mejoradas.
MY187959A (en) Reactor
MX2023009431A (es) Metodo para crear un compuesto a base de mercurio, compuesto a base de mercurio, metodos de uso del compuesto a base de mercurio y usos del compuesto a base de mercurio.
PH12016501201A1 (en) Synthesis of ent-progesterone and intermediates thereof
MX2020002682A (es) Metodos de dosificacion intranasal de metoclopramida.
PH12017500499A1 (en) Synthesis of ent-progesterone and intermediates thereof
PH12018501166B1 (en) Concentrated gibberellin solution formulations
EP4310503A3 (en) Methods related to biologics
MX2015012902A (es) Sintesis de ent-progesterona e intermediarios de la misma.
HK40034301A (en) Methods of intranasal metoclopramide dosing
AU201714572S (en) Jar
IN2014CH00872A (es)